Sdiptech AB (publ) Divestment of Support operations completed – positive effect on profits of SEK 27 million in Q3
5 October 2020, 13:00
Divestment of Support operations completed
– positive effect on profits of SEK 27 million in Q3
Until the spring of 2018, Sdiptech owned a share of a so-called Support operations, which provided administrative services in areas such as law, acquisitions, and marketing communications. Within the Support business, there was also a minority ownership in the product InsiderLog. In order to refine Sdiptech's focus on infrastructure, the shareholding in the Support business was divested in May 2018. As part of the transaction, a few additional conditional payments were included, which have now been realized. This means for the third quarter a total positive effect of approximately SEK 27 million.
Sdiptech's profit from the sale of the Support business can be summed up to SEK 47.7 million, of which SEK 20.9 million has already been booked as realized or expected income. However, these have not affected reported EBITA*. The remaining amount of SEK 26.8 million will have a positive impact on the quarterly result (EBIT) for the third quarter of 2020. The cash settlement of the remaining payment will take place in the spring of 2021.
"The divestment of the Support operations was part of the strategic refinement of Sdiptech's core business towards products and services for critical infrastructure needs. When we now summarize the most important components of the divestment, we can also state that the business itself has made a positive contribution to our result", says Jakob Holm, CEO of Sdiptech.
For additional information, please contact:
Jakob Holm, CEO, +46 761 61 21 91, firstname.lastname@example.org
Bengt Lejdström, CFO, +46 702 74 22 00, email@example.com
Sdiptech's common share of series B share is traded under the short name SDIP B with ISIN code SE0003756758. Sdiptech AB's preferred shares are traded under the short name SDIP PREF with ISIN code SE0006758348. Sdiptech AB's Certified Adviser at Nasdaq First North Premier Growth Market is Erik Penser Bank, +468-463 83 00, firstname.lastname@example.org. Further information is available on the company's website: www.sdiptech.se
Sdiptech AB is a technology group with a primary focus on infrastructure segments critical to well-functioning societies and to welfare, e.g. water & sanitation, power & energy, transportation, energy efficiency and air climate. As part of our offering in urban areas, we also provide niched technical services for buildings and real-estate such as renovation of elevators and roofs. The company has approximately SEK 2,000 million in sales and is based in Stockholm.
The information was provided by the above contact persons for publication 5 October 2020 at 13:00 CEST.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Sinch AB (publ): Sinch announces its intention to carry out a directed new share issue and large shareholders’ intention to sell existing shares to a fund managed by SB Management30.11.2020 17:36:35 CET | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Press Release Stockholm, 30 November Sinch announces its intention to carry out a directed new share issue and large shareholders’ intention to sell existing shares to a fund managed by SB Management Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (“Sinch” or the “Company”) has mandated Carnegie and Handelsbanken Capital Markets (together, the “Joint Bookrunners”) to evaluate the conditions for carrying out a directed issue of approximately 3.2 million new shares, through an accelerated book building process (the “Share Issue”). In connection with the Share Issue, and in order to meet the demand, certain larger shareholders, including s
Sinch AB (publ): Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management30.11.2020 17:36:35 CET | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Pressmeddelande Stockholm den 30 november 2020 Sinch offentliggör sin avsikt att genomföra riktad nyemission och större aktieägares avsikt att sälja befintliga aktier till en fond förvaltad av SB Management Stockholm, Sverige – Sinch AB (publ) – XSTO: SINCH Sinch AB (publ) (”Sinch” eller ”Bolaget”) har uppdragit åt Carnegie och Handelsbanken Capital Markets (tillsammans ”Joint Bookrunners”) att utreda förutsättningarna för att genomföra en riktad nyemission om cirka 3,2 miljoner aktier, genom ett accelererat bookbuilding-förfarande (”Nyemissionen”). I samband med Nyemissionen, och i syfte att möta efterfrågan, har vissa s
Karolinska Developments portföljbolag Aprea Therapeutics erhåller Fast Track designation från FDA för behandling med eprenetapopt vid AML30.11.2020 16:31:31 CET | Pressemelding
STOCKHOLM, SVERIGE 30 november 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat Fast Track designation för portföljbolaget Aprea Therapeutics läkemedelskandidat eprenetapopt vid behandling av TP53-mutant akut myeloisk leukemi (AML). Bolaget har tidigare erhållit Breakthrough-status, särläkemedelsstatus och Fast Track designation för eprenetapopt vid behandling av TP53-mutant myelodysplastiskt syndrom (MDS). FDA:s Fast Track designation är avsedd att underlätta utvecklingen och den regulatoriska granskningen av läkemedelskandidater som adresserar allvarliga sjukdomstillstånd och tillgodoser betydande medicinska behov. En läkemedelskandidat som erhåller Fast Track designation kan vara berättigad till frekventare interaktion med FDA för att diskutera den fortsatta utvecklingsplanen och ger dessutom möjlighet till påskyndad handläggning av en registreringsansökan. Eprenetapopt (APR-246) är en småmolekylär läke
Karolinska Development's portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML30.11.2020 16:31:31 CET | Press release
STOCKHOLM, SWEDEN – November 30, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS). The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditions and address an unmet medical need. A drug candidate that receives Fast Track designation may be eligible for more frequent interaction with the FDA to discuss the drug candidate’s development plan as well as eligibility for accelerated approval and priority review. Eprenetapopt (APR-246) is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restori
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER30.11.2020 16:20:00 CET | Press release
Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure, 2020-12-02CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the latest maturity date as of 2021-06-02 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2020-11-23 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2020-12-02Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid vol
Olainfarm Group maintains its profit forecast, a short term decline in 9 month sales results30.11.2020 15:59:00 CET | Press release
In 2020, the Olainfarm Group continued its ongoing activity in major sales markets. The highest sales in nine months in 2020 was in Latvia, reaching 28 738 thousand EUR, which is 232 thousand EUR or 1% higher than the same period year ago. Latvia sales represent 32% in Group revenues. Sales in Russia for the nine months period in 2020 amount to 20 590 thousand EUR which is a decrease from 2019 due to extra one-off shipment at the end of 2019 for consumption in the first quarter 2020 amounting to 6 million EUR. “Covid-19 pandemic and restrictions due to it have brought different challenges our way, but we understand how to tackle them, and are committed to reach our growth plans outlined in the company's 5-year strategy. As a long-term investment, we have established a subsidiary in Russia, which allows us to get insights from the medical community and market research so that our efforts are relevant and current to customer needs. I am happy to announce that the new business model in Ru